Aprameya Engineering Ltd (APRAMEYA) — shareholding pattern, promoter holding, financials and share price
About Aprameya Engineering Ltd (APRAMEYA)
Aprameya Engineering Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as APRAMEYA and on the BSE under scrip code 77825. Its ISIN is INE0LQG01010.
Incorporated in September 2003, Aprameya Engineering Limited specializes in installing and maintaining Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatres, and prefabricated structure wards in hospitals and medical care centers. [1]
Aprameya Engineering Limited specializes in delivering turnkey projects for hospital infrastructure, including ICUs and Modular Operation Theatres. With strong expertise in healthcare solutions, the company is now diversifying into medical device manufacturing through its subsidiary, Aprameya Medtech Private Limited, marking a strategic expansion. Anticipated 20-25% CAGR over the next three years underlines their high growth trajectory. Targeting Rs 300-350 crore order book, supported by a substantial bid pipeline, is expected to transform its market position significantly. Focused on import substitution, it aims to ramp up production of surgical and specialty equipment.
Listed peers in Medical Equipment & Supplies: Prevest Denpro Ltd, Yash Optics & Lens Ltd, Nureca Ltd, Earkart Limited, QMS Medical Allied Services Ltd, Avience Biomedicals Ltd.
Valuation & Returns
10 Jul 2026At ₹146.15 a share on 10 Jul 2026, Aprameya Engineering Ltd (APRAMEYA) was valued at a price-to-earnings ratio of 54.56x against an industry P/E of 44.11x and a price-to-book of 4.01x on a book value of ₹36.45 per share. Solomo computes return on equity of 7.35% and return on capital employed of 14.27% from filed results.
- P/E
- 54.56x
- Industry P/E
- 44.11x
- P/B
- 4.01x
- EPS (TTM)
- ₹9.27
- Book value / share
- ₹36.45
- ROE
- 7.35%
- ROCE
- 14.27%
- ROA
- 6.24%
- Debt / equity
- 0.1x
- Dividend yield
- 0%
- EBITDA margin
- 19.99%
- 52-week range
- ₹140.25 – ₹360
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aprameya Engineering Ltd (APRAMEYA) reported revenue of ₹55.13 crore, net profit of ₹5.13 crore and earnings per share of ₹2.68. That compares with revenue of ₹135.71 crore and net profit of ₹16.12 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹12.99 crore and net profit ₹-1.63 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 135.71 | 55.13 |
| Net profit (₹ cr) | 16.12 | 5.13 |
| EPS (₹) | 8.47 | 2.68 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 61.81% | 57.10% | 108.27% |
| Profit growth | 89.81% | 29.28% | 361.89% |
| Stock price CAGR | - | - | -8% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 74.05% of Aprameya Engineering Ltd (APRAMEYA). Market capitalisation was ₹278 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Mar 2026: Gaurav Jain 1.21%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 74.05% | - | - | - | - |
| Sep 2025 | 73.53% | - | - | - | - |
| Mar 2025 | 73.53% | - | - | - | - |
| Sep 2024 | 73.53% | - | - | - | - |